Harvard Bioscience (HBIO) EBITDA Margin (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly EBITDA Margin of 5.66% for Q1 2026, up 22245.0% year-over-year from N/an in Q1 2025, and down 178.51% quarter-over-quarter from 7.2% in Q4 2025.
Harvard Bioscience (HBIO) EBITDA Margin (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported EBITDA Margin for 17 consecutive years, with 5.66% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 22245.0% year-over-year to 5.66%; the TTM figure through Mar 2026 stood at 0.1% (up 5854.0% YoY), while the FY2025 annual figure was 56.13%, down 4953.0% from the prior year.
- EBITDA Margin declined to 5.66% in Q1 2026 per HBIO's latest filing, from 7.2% in the prior quarter.
- Across five years, EBITDA Margin topped out at 13.69% in Q2 2022 and bottomed at 228.11% in Q1 2025.
- Historically, EBITDA Margin has averaged 16.21% across 5 years, with a median of 3.68% in 2023.
- Annual changes were most pronounced in 2025 — EBITDA Margin tumbled 21881 bps — and 2026, when it soared 22245 bps.
- Harvard Bioscience's EBITDA Margin stood at 1.61% in 2022, then surged by 162 bps to 1.0% in 2023, then slumped by 96 bps to 0.04% in 2024, then soared by 15983 bps to 7.2% in 2025, then tumbled by 179 bps to 5.66% in 2026.
- Business Quant data shows HBIO's EBITDA Margin at 5.66% in Q1 2026, 7.2% in Q4 2025, and 0.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.71 Bn | 127.50 Bn | 1.96 Bn | 33.60% |
| 2 | Becton Dickinson | 51.57 Bn | 50.71 Bn | 2.32 Bn | 13.31% |
| 3 | Alcon | 35.52 Bn | 34.17 Bn | 1.68 Bn | 0.39% |
| 4 | Resmed | 33.28 Bn | 31.81 Bn | 861.22 Mn | 30.66% |
| 5 | Medline | 27.86 Bn | 25.18 Bn | 2.22 Bn | 5.14% |
| 6 | West Pharmaceutical Services | 25.15 Bn | 24.71 Bn | 329.20 Mn | 20.53% |
| 7 | Solventum | 15.31 Bn | 14.91 Bn | 1.29 Bn | 8.19% |
| 8 | Cooper Companies | 14.86 Bn | 14.72 Bn | 735.40 Mn | -2.87% |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 7.33% |
| 10 | Harvard Bioscience | 34.12 Mn | 27.61 Mn | 12.63 Mn | -4.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.30% |
| Mar 31, 2026 | -5.66% |
| Dec 31, 2025 | 7.20% |
| Sep 30, 2025 | 0.96% |
| Jun 30, 2025 | -4.00% |
| Mar 31, 2025 | -228.11% |
| Dec 31, 2024 | 0.04% |
| Sep 30, 2024 | -8.53% |
| Jun 30, 2024 | -8.96% |
| Mar 31, 2024 | -9.30% |
| Dec 31, 2023 | 1.00% |
| Sep 30, 2023 | -3.68% |
| Jun 30, 2023 | 2.77% |
| Mar 31, 2023 | 5.83% |
| Dec 31, 2022 | -1.61% |
| Sep 30, 2022 | -13.97% |
| Jun 30, 2022 | 13.69% |
| Mar 31, 2022 | -23.32% |
| Dec 31, 2021 | 5.14% |
| Sep 30, 2021 | 1.85% |